JP3587522B2 - インドロカルバゾールイミドおよびその使用 - Google Patents

インドロカルバゾールイミドおよびその使用 Download PDF

Info

Publication number: JP3587522B2
Authority: JP; Japan
Prior art keywords: methyl; carbazole; tetrahydro; indolo; dioxo
Prior art date: 1992-05-30
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Fee Related

Application number

JP50020494A

Other languages

English (en)

Japanese (ja)

Other versions

JPH07508268A (ja

Inventor

クラインシュロース，ユルゲン

シェーヒテル，クリストフ

ハルテンシュテイン，ヨハネス

ルドルフ，クラウス

バールト，フーベルト

アランダ，ユリアン

ベットヒェ，ハンス・ユルゲン

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

KTB Tumorforschungs GmbH

Original Assignee

KTB Tumorforschungs GmbH

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1992-05-30

Filing date

1993-05-28

Publication date

2004-11-10

1993-05-28 Application filed by KTB Tumorforschungs GmbH filed Critical KTB Tumorforschungs GmbH

1995-09-14 Publication of JPH07508268A publication Critical patent/JPH07508268A/ja

2004-11-10 Application granted granted Critical

2004-11-10 Publication of JP3587522B2 publication Critical patent/JP3587522B2/ja

2019-11-10 Anticipated expiration legal-status Critical

Status Expired - Fee Related legal-status Critical Current

Links

0 CC(C(*)=C(*)C12)=C(*)C1N(*)C=C2C(C(N1*)=O)=C(C2=CN(*)C3C(*)=C(*)C(*)=C(*)C23)C1=O Chemical compound CC(C(*)=C(*)C12)=C(*)C1N(*)C=C2C(C(N1*)=O)=C(C2=CN(*)C3C(*)=C(*)C(*)=C(*)C23)C1=O 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Immunology (AREA)
Virology (AREA)
Heart & Thoracic Surgery (AREA)
Cardiology (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Pulmonology (AREA)
Rheumatology (AREA)
Molecular Biology (AREA)
Urology & Nephrology (AREA)
Psychiatry (AREA)
Vascular Medicine (AREA)
Tropical Medicine & Parasitology (AREA)
Pain & Pain Management (AREA)
AIDS & HIV (AREA)
Hospice & Palliative Care (AREA)
Transplantation (AREA)
Dermatology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

JP50020494A 1992-05-30 1993-05-28 インドロカルバゾールイミドおよびその使用 Expired - Fee Related JP3587522B2 (ja)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
DE4217964.5		1992-05-30
DE4217964A DE4217964A1 (de)	1992-05-30	1992-05-30	Indolocarbazol-Imide und deren Verwendung
PCT/EP1993/001347 WO1993024491A1 (fr)	1992-05-30	1993-05-28	Indolocarbazol-imides et leur utilisation

Related Child Applications (1)

Application Number	Title	Priority Date	Filing Date
JP2003285658A Division JP2004026842A (ja)	1992-05-30	2003-08-04	インドロカルバゾールイミドおよびその使用

Publications (2)

Publication Number	Publication Date
JPH07508268A JPH07508268A (ja)	1995-09-14
JP3587522B2 true JP3587522B2 (ja)	2004-11-10

Family

ID=6460104

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
JP50020494A Expired - Fee Related JP3587522B2 (ja)	1992-05-30	1993-05-28	インドロカルバゾールイミドおよびその使用
JP2003285658A Pending JP2004026842A (ja)	1992-05-30	2003-08-04	インドロカルバゾールイミドおよびその使用

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
JP2003285658A Pending JP2004026842A (ja)	1992-05-30	2003-08-04	インドロカルバゾールイミドおよびその使用

Country Status (18)

Country	Link
US (2)	US5883114A (fr)
EP (1)	EP0642513B1 (fr)
JP (2)	JP3587522B2 (fr)
KR (1)	KR950701811A (fr)
AT (1)	ATE195315T1 (fr)
AU (1)	AU687350B2 (fr)
CA (1)	CA2135768C (fr)
CZ (1)	CZ295394A3 (fr)
DE (2)	DE4217964A1 (fr)
DK (1)	DK0642513T3 (fr)
ES (1)	ES2152252T3 (fr)
FI (1)	FI945625A0 (fr)
HU (1)	HUT71102A (fr)
NO (1)	NO302574B1 (fr)
NZ (1)	NZ253090A (fr)
RU (1)	RU2126007C1 (fr)
SK (1)	SK146394A3 (fr)
WO (1)	WO1993024491A1 (fr)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5461146A (en) *	1992-07-24	1995-10-24	Cephalon, Inc.	Selected protein kinase inhibitors for the treatment of neurological disorders
WO1994005283A1 (fr) *	1992-09-02	1994-03-17	Kyowa Hakko Kogyo Co., Ltd.	Medicament anti-vih
DE4243321A1 (de) *	1992-12-21	1994-06-23	Goedecke Ag	Aminosäurederivate von Heterocyclen als PKC-Inhibitoren
US5468872A (en) *	1993-09-16	1995-11-21	Cephalon, Inc.	K-252a functional derivatives potentiate neurotrophin-3 for the treatment of neurological disorders
US5491242A (en) *	1994-06-22	1996-02-13	Eli Lilly And Company	Protein kinase C inhibitors
EP0695755B1 (fr) *	1994-08-04	1998-10-21	F. Hoffmann-La Roche AG	Pyrrolocarbazole
JP4070810B2 (ja) *	1995-12-11	2008-04-02	セファロン・インコーポレイテッド	タンパク質キナーゼｃの阻害剤としての縮合イソインドロン
WO1997041854A1 (fr) *	1996-05-07	1997-11-13	The Trustees Of The University Of Pennsylvania	Inhibiteurs de glycogene synthetase kinase-3 et procedes d'identification et d'utilisation de ces inhibiteurs
PE91598A1 (es)	1996-07-29	1998-12-24	Hoffmann La Roche	Pirroles sustituidos
PE91698A1 (es) *	1996-07-29	1998-12-24	Hoffmann La Roche	Pirroles sustituidos
PE91498A1 (es) *	1996-07-29	1998-12-22	Hoffmann La Roche	Pirroles sustituidos
DE19917990A1 (de) *	1999-04-20	2000-11-02	Florian Lang	Arzneimittel enthaltend Hemmstoffe der zellvolumenregulierten humanen Kinase h-sgk
US6281356B1 (en) *	1999-12-22	2001-08-28	Hoffmann-La Roche Inc.	Substituted pyrroles
US7122679B2 (en) *	2000-05-09	2006-10-17	Cephalon, Inc.	Multicyclic compounds and the use thereof
CA2308994A1 (fr) *	2000-05-19	2001-11-19	Aegera Therapeutics Inc.	Composes neuroprotecteurs
US7129250B2 (en) *	2000-05-19	2006-10-31	Aegera Therapeutics Inc.	Neuroprotective and anti-proliferative compounds
ES2189597B2 (es) *	2000-07-18	2004-06-16	Fundacion Universitaria San Pablo-Ceu	Derivados de 12,13-dihidro-5h-indolo(2,3-a)pirrolo(3,4-c)carbazol-5,7(6h)-diona como agentes antineoplasicos.
AU2001292579A1 (en) *	2000-09-29	2002-04-15	Eli Lilly And Company	Methods and compounds for treating proliferative diseases
KR100446090B1 (ko) *	2000-10-19	2004-08-30	주식회사 엘컴사이언스	사우로락탐계 알카로이드의 퇴행성 뇌신경계 질환의 예방과 치료제로서의 용도 및 이 화합물을 유효성분으로 함유하는 약학적 제제
AU4344202A (en)	2000-10-31	2002-06-24	Advanced Life Sciences Inc	Indolocarbazole anticancer agents and methods of using them
US7122526B2 (en) *	2000-10-31	2006-10-17	Nanosphere, Inc.	Indolocarbazole anticancer agents and methods of using same
EP2070921A1 (fr) *	2000-11-07	2009-06-17	Novartis Ag	Dérivés d'indolylmaléimide comme inhibiteurs de la protéine kinase C
US6710068B2 (en)	2001-04-11	2004-03-23	Idenix Pharmaceuticals, Inc.	Phenylindoles for the treatment of HIV
EP1432721A4 (fr) *	2001-09-13	2008-02-20	Bristol Myers Squibb Co	Procede de preparation de rebeccamycine et d'analogues correspondants
TW201041580A (en)	2001-09-27	2010-12-01	Alcon Inc	Inhibitors of glycogen synthase kinase-3 (GSK-3) for treating glaucoma
DE10161940A1 (de) *	2001-12-17	2003-07-03	Nad Ag	N-Carbacyclus-monosubstitutierte Indolocarbazole als Proteinkinase-inhibitoren
FR2833840B1 (fr) *	2001-12-21	2010-06-18	Rytek	Methodes et compositions pour le traitement de pathologies respiratoires
JP2006500355A (ja) *	2002-08-07	2006-01-05	イデニクス（ケイマン）リミテツド	Ｈｉｖ治療用の置換フェニルインドール類
CA2522712A1 (fr) *	2003-04-18	2004-10-28	Kyowa Hakko Kogyo Co., Ltd.	Medicament pour la regeneration des nerfs
BRPI0515344A (pt) *	2004-09-17	2008-07-15	Idenix Pharmaceuticals Inc	composto, composição farmacêutica, e, usos de uma quantidade eficaz de um composto 3-fosfoindol ou sal, pró-droga, estereoisÈmero, tautÈmero, n-óxido ou amina quaternária farmaceuticamente aceitável do mesmo e de uma quantidade de tratamento eficaz anti-hiv de um composto de 3-fosfoindol ou sal, pró-droga, estereo-isÈmero, tautÈmero, n-óxido ou amina quaternária farmaceuticamente aceitável do mesmo
FR2879100B1 (fr) *	2004-12-09	2007-07-06	Lionel Bueno	Compositions pour le traitement des pathologies oculaires de surface et de la retine
US20070249590A1 (en) *	2005-10-28	2007-10-25	Wilson Lawrence J	Substituted indolo[2,3-a]pyrrolo[3,4-c]carbazole compounds useful in treating kinase disorders
JP2010504978A (ja)	2006-09-29	2010-02-18	アイデニクスファーマシューティカルズ，インコーポレーテッド	Ｈｉｖ阻害剤としての鏡像異性的に純粋なホスホインドール
EP2047849A1 (fr) *	2007-10-08	2009-04-15	KTB Tumorforschungsgesellschaft mbH	Utilisation d'imides d'indolocarbazole en tant qu'inhibiteurs de protéine kinase pour le traitement des tumeurs solides et hématologiques
EP3741375A1 (fr)	2014-07-17	2020-11-25	INSERM (Institut National de la Santé et de la Recherche Médicale)	Procédés de traitement de maladies associées aux jonctions neuromusculaires
WO2016207366A1 (fr)	2015-06-26	2016-12-29	INSERM (Institut National de la Santé et de la Recherche Médicale)	Méthodes et compositions pharmaceutiques de traitement d'infections virales
CN107556323B (zh) *	2017-08-30	2019-09-20	浙江大学	一种氨基取代星孢菌素类化合物及其制备方法和应用
EP3706735A1 (fr) *	2017-11-06	2020-09-16	Snap Bio, Inc.	Compositions d'inhibiteur de kinase pim, procédés et utilisations de celles-ci
CN113980000B (zh) *	2021-12-30	2022-05-20	北京鑫开元医药科技有限公司	甲基酮类衍生物、制备方法、药物组合物及应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JP3010675B2 (ja) *	1989-03-23	2000-02-21	萬有製薬株式会社	抗腫瘍性物質ｂｅ―１３７９３ｃ
US5217885A (en) *	1989-03-23	1993-06-08	Banyu Pharmaceutical Co., Ltd.	Antitumor substance BE-13793C
EP0528030B1 (fr) *	1990-05-11	1997-09-17	Banyu Pharmaceutical Co., Ltd.	Derive antitumoral de be-13793c
US5547976A (en) *	1992-03-20	1996-08-20	Burroughs Wellcome Co.	Further indole derivatives with antiviral activity

1992
- 1992-05-30 DE DE4217964A patent/DE4217964A1/de not_active Withdrawn
1993
- 1993-05-28 DE DE59310085T patent/DE59310085D1/de not_active Expired - Fee Related
- 1993-05-28 EP EP93912820A patent/EP0642513B1/fr not_active Expired - Lifetime
- 1993-05-28 FI FI945625A patent/FI945625A0/fi unknown
- 1993-05-28 ES ES93912820T patent/ES2152252T3/es not_active Expired - Lifetime
- 1993-05-28 KR KR1019940704352A patent/KR950701811A/ko not_active Ceased
- 1993-05-28 AU AU43194/93A patent/AU687350B2/en not_active Ceased
- 1993-05-28 CA CA002135768A patent/CA2135768C/fr not_active Expired - Fee Related
- 1993-05-28 HU HU9403419A patent/HUT71102A/hu unknown
- 1993-05-28 US US08/343,435 patent/US5883114A/en not_active Expired - Fee Related
- 1993-05-28 NZ NZ253090A patent/NZ253090A/en unknown
- 1993-05-28 JP JP50020494A patent/JP3587522B2/ja not_active Expired - Fee Related
- 1993-05-28 DK DK93912820T patent/DK0642513T3/da active
- 1993-05-28 WO PCT/EP1993/001347 patent/WO1993024491A1/fr not_active Ceased
- 1993-05-28 RU RU94046306A patent/RU2126007C1/ru not_active IP Right Cessation
- 1993-05-28 CZ CZ942953A patent/CZ295394A3/cs unknown
- 1993-05-28 SK SK1463-94A patent/SK146394A3/sk unknown
- 1993-05-28 AT AT93912820T patent/ATE195315T1/de not_active IP Right Cessation
1994
- 1994-11-29 NO NO944564A patent/NO302574B1/no not_active IP Right Cessation
1998
- 1998-05-07 US US09/074,139 patent/US5945440A/en not_active Expired - Fee Related
2003
- 2003-08-04 JP JP2003285658A patent/JP2004026842A/ja active Pending

Also Published As

Publication number	Publication date
JP2004026842A (ja)	2004-01-29
US5945440A (en)	1999-08-31
FI945625L (fi)	1994-11-29
NO944564D0 (no)	1994-11-29
WO1993024491A1 (fr)	1993-12-09
RU94046306A (ru)	1996-10-27
JPH07508268A (ja)	1995-09-14
CA2135768A1 (fr)	1993-12-01
HU9403419D0 (en)	1995-02-28
US5883114A (en)	1999-03-16
KR950701811A (ko)	1995-05-17
NO944564L (no)	1995-01-30
SK146394A3 (en)	1995-08-09
RU2126007C1 (ru)	1999-02-10
NZ253090A (en)	1997-02-24
EP0642513B1 (fr)	2000-08-09
CA2135768C (fr)	2004-11-23
DE4217964A1 (de)	1993-12-02
FI945625A7 (fi)	1994-11-29
ES2152252T3 (es)	2001-02-01
DK0642513T3 (da)	2001-01-02
AU687350B2 (en)	1998-02-26
ATE195315T1 (de)	2000-08-15
CZ295394A3 (en)	1995-03-15
EP0642513A1 (fr)	1995-03-15
DE59310085D1 (de)	2000-09-14
NO302574B1 (no)	1998-03-23
AU4319493A (en)	1993-12-30
FI945625A0 (fi)	1994-11-29
HUT71102A (en)	1995-11-28

Legal Events

Date	Code	Title	Description
2004-01-07	A131	Notification of reasons for refusal	Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040106
2004-04-15	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040329
2004-07-01	A601	Written request for extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040329
2004-07-06	A521	Request for written amendment filed	Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20040705
2004-07-09	A602	Written permission of extension of time	Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20040708
2004-07-30	TRDD	Decision of grant or rejection written
2004-08-04	A01	Written decision to grant a patent or to grant a registration (utility model)	Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20040803
2004-08-19	A61	First payment of annual fees (during grant procedure)	Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20040810
2004-08-20	R150	Certificate of patent or registration of utility model	Free format text: JAPANESE INTERMEDIATE CODE: R150
2007-08-21	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20080820 Year of fee payment: 4
2008-07-31	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20080820 Year of fee payment: 4
2008-08-05	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20090820 Year of fee payment: 5
2009-05-19	FPAY	Renewal fee payment (event date is renewal date of database)	Free format text: PAYMENT UNTIL: 20100820 Year of fee payment: 6
2010-08-20	LAPS	Cancellation because of no payment of annual fees

Publication	Publication Date	Title
JP3587522B2 (ja)	2004-11-10	インドロカルバゾールイミドおよびその使用
AU2011288876B2 (en)	2014-08-21	Phthalazinone ketone derivative, preparation method thereof, and pharmaceutical use thereof
CN113683616A (zh)	2021-11-23	Kras g12c突变蛋白抑制剂
CN104066723B (zh)	2016-06-29	1-(芳基甲基)-5,6,7,8-四氢喹唑啉-2,4-二酮和相关化合物及其应用
KR20100100771A (ko)	2010-09-15	Ｐａｒｐ 억제제 화합물, 조성물 및 사용 방법
JP2004507439A (ja)	2004-03-11	Ｘａ因子阻害剤としての窒素含有ヘテロ二環式化合物
BG64838B1 (bg)	2006-06-30	Производни на индолил-3-глиоксиловата киселина с антитуморно действие
US5438050A (en)	1995-08-01	Indolocarbazole derivatives, processes for their preparation and compositions containing them
KR20010085305A (ko)	2001-09-07	이치환된 말레이미드 화합물 및 그의 의약 용도
US5489608A (en)	1996-02-06	Indolocarbazole derivatives and the use thereof
FR2940284A1 (fr)	2010-06-25	Derives de 6-cycloamino-2,3-di-pyridinyl-imidazo°1,2-b!- pyridazine,leur preparation et leur application en therapeutique
WO2003066622A1 (fr)	2003-08-14	Nouveaux composes de benzimidazole
WO1993003031A1 (fr)	1993-02-18	Derive de pyrroloazepine
CN113527300A (zh)	2021-10-22	布鲁顿酪氨酸蛋白激酶抑制剂
CN111116572B (zh)	2023-10-27	噁二唑衍生物及其制备方法和用途
WO2004047769A2 (fr)	2004-06-10	Benzimidazoles et analogues de ceux-ci utilises comme agents anti-bacteriens
HUP0003991A2 (en)	2002-06-29	Serotonin-reuptake inhibitor ciano-indole derivatives, process for their preparation and pharmaceutical compositions containing them
US7662824B2 (en)	2010-02-16	Acylhydrazones as kinase modulators
RU2610275C2 (ru)	2017-02-08	Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения
KR100874209B1 (ko)	2008-12-15	3,10-다이하이드로-1Ｈ-[1,4]다이아제피노[5,6-ｂ]인돌-2-온 유도체 및 약학적으로 허용 가능한 염, 그의 제조방법및 그의 용도
BRPI0619955A2 (pt)	2011-10-25	derivados tricìclicos da lactama, sua produção e seus usos como agentes farmacêuticos
RU2610274C2 (ru)	2017-02-08	Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения
RU2610276C1 (ru)	2017-02-08	Производное глутаримидов, его применение, фармацевтическая композиция на его основе, способ его получения
CA2322790C (fr)	2008-06-10	Derives de granulatimide utilises dans le traitement du cancer
CN120004863A (zh)	2025-05-16	一种alk蛋白降解剂及其在抗肿瘤中的应用